You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Relapsed Lymphoma

Showing 1 - 25 of 9,146
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Relapsed or Refractory CD19+ B-cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small

Recruiting
  • Relapsed or Refractory CD19+ B-cell Lymphoma
  • +2 more
  • TBI-2001
  • +2 more
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
Jul 26, 2023

Relapsed or Refractory Diffuse Large B-cell Lymphoma Trial in Beijing (BEBT-908 for injection)

Active, not recruiting
  • Relapsed or Refractory Diffuse Large B-cell Lymphoma
  • BEBT-908 for injection
  • Beijing, China
    Cancer Hospital Chinese Academy of Medical Sciences
Oct 8, 2023

Relapsed or Refractory B-cell Lymphoma Trial in Guangzhou (infusion of JY231 injection)

Recruiting
  • Relapsed or Refractory B-cell Lymphoma
  • infusion of JY231 injection
  • Guangzhou, Guangdong, China
    Guangdong Second Provincial General Hospital
Sep 17, 2023

Relapsed or Refractory B-cell Lymphoma Trial (Relmacabtagene Autoleucel Injection)

Not yet recruiting
  • Relapsed or Refractory B-cell Lymphoma
  • Relmacabtagene Autoleucel Injection
  • (no location specified)
Apr 13, 2023

Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma, Refractory T-Cell Lymphoma Trial in Xiamen (Chidamide combined

Recruiting
  • Peripheral T Cell Lymphoma
  • +2 more
  • Chidamide combined with Duvillisib
  • Xiamen, Fujian, China
    The First Affiliated Hosptial of Xiamen University
Nov 28, 2023

Relapsed/Refractory B-Cell Lymphoma Trial (FT522, Rituximab, Cyclophosphamide)

Not yet recruiting
  • Relapsed/Refractory B-Cell Lymphoma
  • (no location specified)
Jul 10, 2023

Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) Trial (GFH009)

Not yet recruiting
  • Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
  • (no location specified)
Jun 28, 2023

Relapsed or Refractory Hodgkin Lymphoma Trial in Beijing (SHR2554+ SHR1701, SHR-1701)

Recruiting
  • Relapsed or Refractory Hodgkin Lymphoma
  • Beijing, Beijing, China
    Han wei dong
Jun 14, 2023

Mantle-cell Lymphoma Trial (Polatuzumab, bendamustin und rituximab)

Not yet recruiting
  • Mantle-cell Lymphoma
  • Polatuzumab, bendamustin und rituximab
  • (no location specified)
May 11, 2023

Diffuse Large B Cell Lymphoma | DLBCL Recurrent/Refractory Trial (ZR2-ICE)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma | Diffuse Large B-Cell Lymphoma Recurrent/Refractory
  • (no location specified)
Sep 5, 2023

Relapsed/Refractory Large B-cell Lymphoma Trial (KITE-197, Cyclophosphamide, Fludarabine)

Not yet recruiting
  • Relapsed/Refractory Large B-cell Lymphoma
  • (no location specified)
Oct 6, 2023

SALVAGE TREATMENT WITH GLOFITAMAB IN RELAPSED/REFRACTORY B-NHL:

Not yet recruiting
  • B-cell Non Hodgkin Lymphoma
  • +2 more
    • (no location specified)
    Jun 22, 2023

    Lymphoma, Primary Effusion Trial run by the National Cancer Institute (NCI) (Daratumumab SC)

    Not yet recruiting
    • Lymphoma, Primary Effusion
    • Daratumumab SC
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Jun 23, 2023

    Relapsed/Refractory Non-Hodgkin Lymphoma Trial in Duarte, Amsterdam (BMS-986458, Rituximab)

    Not yet recruiting
    • Relapsed/Refractory Non-Hodgkin Lymphoma
    • Duarte, California
    • +1 more
    Oct 13, 2023

    Non-hodgkin Lymphoma Trial (HY004)

    Not yet recruiting
    • Non-hodgkin Lymphoma
    • HY004
    • (no location specified)
    Aug 21, 2023

    Relapsed or Refractory B-cell Lymphoma Trial in Shanghai (SR-GDP)

    Not yet recruiting
    • Relapsed or Refractory B-cell Lymphoma
    • Shanghai, Shanhai, China
      Ruijin Hospital
    Sep 29, 2023

    Relapsed or Refractory (R/R) Primary CNS Lymphoma Trial in Nanjing (thiotepa combined with pomalidomide)

    Recruiting
    • Relapsed or Refractory (R/R) Primary Central Nervous System Lymphoma
    • thiotepa combined with pomalidomide
    • Nanjing, Jiangsu, China
      Jiangsu Province People's Hospital.
    Jun 27, 2023

    Refractory or Relapsed B-cell Non-Hodgkin Lymphoma Trial in Shanghai (dualCAR-NK19/70 cell)

    Recruiting
    • Refractory or Relapsed B-cell Non-Hodgkin Lymphoma
    • dualCAR-NK19/70 cell
    • Shanghai, Shanghai, China
      Shanghai Tongji Hospital, Tongji University School of Medicine
    Apr 24, 2023

    Relapsed or Refractory B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL) Trial in Beijing

    Recruiting
    • Relapsed or Refractory B-cell Lymphoma
    • +6 more
    • Beijing, China
      Beijing Cancer Hospital
    Feb 6, 2023

    Diffuse Large B-cell Lymphoma Recurrent, Diffuse Large B Cell Lymphoma Refractory Trial in Hangzhou (Anlotinib HCl, Rituximab,

    Recruiting
    • Diffuse Large B-cell Lymphoma Recurrent
    • Diffuse Large B Cell Lymphoma Refractory
    • Anlotinib hydrochloride, Rituximab, gemcitabine, oxaliplatin
    • Hangzhou, Zhejiang, China
      Zhejiang Cancer Hospital
    Oct 12, 2023

    Lymphoma, Non-Hodgkin's, Adult Trial (SP-3164)

    Not yet recruiting
    • Lymphoma, Non-Hodgkin's, Adult
    • (no location specified)
    Aug 4, 2023

    Non-hodgkin's Lymphoma Trial in Beijing (GNC-035)

    Not yet recruiting
    • Non-hodgkin's Lymphoma
    • Beijing, Beijing, China
      Beijing Cancer Hospital
    Sep 27, 2023

    Adult Patients With Diagnosed Relapsed or Refractory B-cell Lymphoma Who Have Completed Their First Treatment With Regiorense

    Recruiting
    • Adult Patients With Diagnosed Relapsed or Refractory B-cell Lymphoma Who Have Completed Their First Treatment With Regiorense Injection
    • Relmacabtagene Autoleucel Injection
    • Shanghai, Shanghai, China
      NO.197， Ruijin Er Road
    Mar 28, 2023

    Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL) Trial (Fludarabine (30 mg/m^2), Cyclophosphamide (500 mg/m^2), CRG-022

    Not yet recruiting
    • Cancer
    • Relapsed/Refractory Large B-cell Lymphoma (LBCL)
    • Fludarabine (30 mg/m^2)
    • +2 more
    • (no location specified)
    Jul 25, 2023

    Diffuse Large B Cell Lymphoma Trial in Shanghai (Zanubrutinib, Polatuzumab vedotin and Rituximab)

    Recruiting
    • Diffuse Large B Cell Lymphoma
    • Zanubrutinib, Polatuzumab vedotin and Rituximab
    • Shanghai, Shanghai, China
      Zhongshan Hospital，Fudan University
    Jul 10, 2023